Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole

Fig. 1

Changes in symptom severity scores between Responders and Non-Responders taking aripiprazole. Symptoms were rated on a scale of 0 (no symptom) to 10 (worst). For responders, average fatigue score changed by − 2.89 units (p < 0.001), brain fog changed by − 2.33 units (p < 0.001), and unrefreshing sleep changed by − 2.05 units (p < 0.001). Non-Responders showed non-significant differences of − 0.2 units for fatigue, (p = 1), − 0.65 units for brain fog (p = 0.289), and = 0.42 for unrefreshing sleep (p = 0.4105)

Back to article page